• In early August 2026, Twist Bioscience completed a US$300 million follow-on common stock offering at US$96 per share while raising its fiscal 2026 revenue guidance to US$456 million–US$457 million and reporting a wider quarterly net loss despite higher sales.
• At the same time, the company moved to resolve legacy securities litigation through a proposed US$17.05 million class-action settlement process, potentially reducing legal uncertainty for shareholders.
• With Twist boosting revenue guidance and raising fresh equity capital, we’ll now examine how this funding shift affects its existing investment narrative.

AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Twist Bioscience Investment Narrative Recap

To own Twist Bioscience, you have to believe its synthetic DNA platform can scale into a much larger, more diversified business while eventually narrowing losses. The latest US$300 million equity raise and higher 2026 revenue guidance do not change the central short term catalyst, which is progress toward improved profitability, but they partly ease the immediate risk of another near term funding crunch while reinforcing the ongoing concern about dilution.

The most relevant recent announcement here is the raised fiscal 2026 revenue guidance to US$456 million to US$457 million, alongside a wider quarterly net loss. That combination highlights the current trade off: strong top line momentum in areas like NGS and SynBio versus a business model that is still absorbing heavy costs to grow. How effectively Twist converts this guided revenue into better margins remains central to whether the follow on capital ultimately supports shareholder value.

Yet despite the stronger balance sheet and higher revenue guidance, investors should still pay close attention to the unresolved risk that...

Twist Bioscience's narrative projects $666.9 million revenue and $113.3 million earnings by 2029. This requires 17.7% yearly revenue growth and a $194.6 million earnings increase from -$81.3 million today.

Uncover how Twist Bioscience's forecasts yield a $92.50 fair value, a 20% downside to its current price.

Exploring Other Perspectives

Some of the lowest analysts were already assuming only about 15 percent annual revenue growth to roughly US$600.6 million by 2029 and no profits before then, so this fresh capital and higher 2026 guidance could either ease their concerns or reinforce them depending on how you view dilution and execution, which is why it is worth comparing these more pessimistic expectations with your own.

Explore 4 other fair value estimates on Twist Bioscience - why the stock might be worth as much as 76% more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Twist Bioscience research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Twist Bioscience research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Twist Bioscience's overall financial health at a glance.

Looking For Alternative Opportunities?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.
• Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.